Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month High After Analyst Upgrade

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) hit a new 52-week high on Friday after Needham & Company LLC raised their price target on the stock from $55.00 to $58.00. Needham & Company LLC currently has a buy rating on the stock. Xenon Pharmaceuticals traded as high as $46.99 and last traded at $44.78, with a volume of 461795 shares changing hands. The stock had previously closed at $44.92.

Several other equities analysts have also recently issued reports on XENE. JPMorgan Chase & Co. upped their price target on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Wolfe Research assumed coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price objective on the stock. Royal Bank Of Canada increased their price objective on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, November 4th. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and an average price target of $55.50.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the sale, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $266,580. This represents a 86.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 65,205 shares of company stock valued at $2,919,762 in the last quarter. 4.07% of the stock is owned by insiders.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Two analyst upgrades lift sentiment — Needham raised its price target to $58 with a Buy rating and Wells Fargo nudged its target to $49 with an Overweight rating, implying meaningful upside from current levels, which supports longer-term investor interest. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Company update highlights near-term clinical catalysts and strong pro forma cash runway — Xenon reiterated a Phase 3 topline readout for azetukalner (X-TOLE2) expected in early March and reported pro forma cash (~$716M) that management says extends runway into H2 2027, reducing near-term financing risk and keeping the pipeline-funded. Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst/press commentary stresses pipeline focus despite higher R&D — Coverage (e.g., Zacks) notes a wider Q4 loss driven by a 47% jump in R&D spend but underscores ongoing late‑stage azetukalner trials and early-stage pain programs; useful context but not an immediate stock mover beyond the earnings reaction. Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
• Negative Sentiment: Refreshed $400M at-the-market (ATM) equity program — Xenon filed to refresh an ATM capacity, which increases the potential for share issuance. While it provides financing optionality, investors often view ATM refreshes as a near-term dilution risk that can pressure the stock. Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program
• Negative Sentiment: Q4 EPS missed estimates — Xenon reported ($1.31) EPS vs. consensus ($1.20), a larger loss year-over-year; the miss likely contributed to intra-day selling despite the pipeline updates. Xenon Reports Q4 and Full Year 2025 Financial Results (Press Release PDF)

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Holocene Advisors LP acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth approximately $56,637,000. Wellington Management Group LLP lifted its holdings in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares in the last quarter. Geode Capital Management LLC grew its position in Xenon Pharmaceuticals by 1,294.2% in the 2nd quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after purchasing an additional 900,746 shares during the period. Braidwell LP increased its stake in Xenon Pharmaceuticals by 33.0% during the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after purchasing an additional 895,154 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Xenon Pharmaceuticals by 1,968.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after buying an additional 820,608 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Down 3.8%

The stock has a market capitalization of $3.34 billion, a P/E ratio of -9.92 and a beta of 0.96. The business’s 50 day simple moving average is $42.49 and its two-hundred day simple moving average is $41.04.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the prior year, the business posted ($0.84) EPS. Analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.